---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-010410"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:53:12.613188+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Neoleukin appoints interim CEO and CFO after Drachman resignation; CMO Patel departs

## Summary
- Donna Cochener appointed Interim CEO; Sean Smith appointed Interim CFO, effective March 31, 2023.
- Dr. Jonathan Drachman resigned as President, CEO and director, effective March 31, 2023 (previously announced March 6).
- Cochener receives base salary $450,000; Smith $410,000; annual bonuses and retention bonuses up to $219,375 and $159,167 respectively.
- CMO Dr. Priti Patel separated; receives 9 months salary continuation, healthcare, and accelerated vesting of 100,000 options.
- Interim officers' severance: 9 months salary plus COBRA; enhanced 15 months lump sum on change of control.

## SEC filing metadata
- accession: 0001628280-23-010410
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/nltx-20230403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-010410
- JSON: https://secwatch.observer/filing/0001628280-23-010410.json
- Plain text: https://secwatch.observer/filing/0001628280-23-010410.txt

## Key facts
- Executive change
  Donna M. Cochener was appointed as Interim Chief Executive Officer at Neurogene Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: the Board of Directors (the "Board") of Neoleukin Therapeutics, Inc. (the "Company") appointed (a) Donna M. Cochener as the Company’s Interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm
- Executive change
  Jonathan Drachman resigned as President, Chief Executive Officer, principal executive and financial officer and director at Neurogene Inc..
  - Action: resigned
  - Role: President, Chief Executive Officer, principal executive and financial officer and director
  source text: Dr. Jonathan Drachman, M.D.'s resignation from his role as President, Chief Executive Officer, principal executive and financial officer and director of the Company as of the Effective Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000162828023010410/0001628280-23-010410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.